玻璃体腔注射康柏西普对黄斑水肿患者角膜厚度和内皮细胞的影响
|
摘要
目的:研究玻璃体腔注射康柏西普对黄斑水肿患者角膜厚度及内皮细胞的影响。方法:选取2017-01/12在本院行玻璃体腔注射康柏西普治疗黄斑水肿的患者30例30眼,手术前后使用超声生物显微镜测量中央角膜厚度,使用角膜内皮计数仪测量患眼中央角膜内皮细胞密度和六角形细胞比例。结果:本组患者术前和术后1d,1wk角膜中央厚度分别为551.68±12.80、552.06±13.22、552.49±13.83μm(P>0.05)。术前和术后1d,1wk,3、6mo中央角膜内皮细胞密度分别为2551.03±287.55、2563.79±292.34、2543.32±282.41、2526.18±280.24、2519.60±279.89个/mm~2,六角形细胞比例分别为(50.23±7.51)%、(50.93±8.23)%、(50.60±7.91)%、(50.40±7.50)%、(50.93±8.19)%,均无明显差异(P>0.05)。结论:玻璃体腔注射康柏西普是一种安全的治疗黄斑水肿的方法,在注射后6mo内对角膜厚度及内皮细胞无明显影响。
AIM: To study the effect of intravitreal conbercept on corneal thickness and endothelial cells in macular edema patients.METHODS:Intravitreal conbercept was performed on 30 eyes of 30 patients with macular edema due to different diseases from Jan. 2017 to Dec. 2017 in our hospital. The central corneal thickness was identified by ultrasonic biomicroscope(UBM) before and after surgery. Specular microscopy was also used to detect the density of central corneal endothelial cells and proportion of hexagonal cells before and after surgery.RESULTS:The central corneal thickness were 551.68±12.80μm before surgery, 552.06±13.22μm at the first day after surgery and 552.49±13.83μm at 1 wk after surgery(P>0.05). The density of central corneal were 2551.03±287.55/mm~2 before surgery, and 2563.79±292.34, 2543.32±282.41, 2526.18±280.24, 2519.60±279.89/mm~2 at 1 d, 1 wk, 3 mo and 6 mo after surgery respectively, meanwhile, the proportion of hexagonal cells were(50.23±7.51)% before surgery, and(50.93±8.23)%,(50.60±7.91)%,(50.40±7.50)%,(50.93±8.19)% at 1 d, 1 wk, 3 mo and 6 mo after surgery respectively(P>0.05).CONCLUSION: Intravitreal injections of conbercept demonstrated a safety in the treatment of macular edema. It seems no affects on corneal thickness and corneal endothelial cells at 6 mo after intravitreal conbercept.
AIM: To study the effect of intravitreal conbercept on corneal thickness and endothelial cells in macular edema patients.METHODS:Intravitreal conbercept was performed on 30 eyes of 30 patients with macular edema due to different diseases from Jan. 2017 to Dec. 2017 in our hospital. The central corneal thickness was identified by ultrasonic biomicroscope(UBM) before and after surgery. Specular microscopy was also used to detect the density of central corneal endothelial cells and proportion of hexagonal cells before and after surgery.RESULTS:The central corneal thickness were 551.68±12.80μm before surgery, 552.06±13.22μm at the first day after surgery and 552.49±13.83μm at 1 wk after surgery(P>0.05). The density of central corneal were 2551.03±287.55/mm~2 before surgery, and 2563.79±292.34, 2543.32±282.41, 2526.18±280.24, 2519.60±279.89/mm~2 at 1 d, 1 wk, 3 mo and 6 mo after surgery respectively, meanwhile, the proportion of hexagonal cells were(50.23±7.51)% before surgery, and(50.93±8.23)%,(50.60±7.91)%,(50.40±7.50)%,(50.93±8.19)% at 1 d, 1 wk, 3 mo and 6 mo after surgery respectively(P>0.05).CONCLUSION: Intravitreal injections of conbercept demonstrated a safety in the treatment of macular edema. It seems no affects on corneal thickness and corneal endothelial cells at 6 mo after intravitreal conbercept.
引文
1 Acar U,Erginturk Acar D,Alpaslan Pinarli F,et al. Effect of commonly used intravitreal anti-vascular endothelial growth factor drugs on mesenchymal stem cells derived from the limbus and ciliary body. Clin Exp Ophthalmol 2016;44(7):587-596
2 Hosny MH,Zayed MA,Shalaby AM,et al. Effect of intracameral bevacizumab injection on corneal endothelial cells:an in vivo evaluation. J Ocul Pharmacol Ther 2009;25(6):513-517
3 Li H,Lei N,Zhang M,et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012;97(1):154-159
4 Cui J,Sun D,Lu H,et al. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye(Lond) 2018;32(2):391-399
5 Xu Y,Rong A,Xu W,et al. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study. BMC Ophthalmol 2017;17(1):158
6 Qiao G,Dong WJ,Dai Y,et al. Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies. Int J Ophthalmol 2017;10(7):1113-1119
7詹磊,熊思盈,甘孟欣,等.玻璃体切割联合白内障手术对DR患者角膜内皮细胞的影响.国际眼科杂志 2017; 17(8):1529-1531
8 Han KY,Chang JH,Lee H,et al. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci 2016;57(7):3313-3322
9 Zhang X,Di G,Dong M,et al. Epithelium-derived miR-204 inhibits corneal neovascularization. Exp Eye Res 2018;167:122-127
10 Ari S,Nergiz Y,Aksit I,et al. Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy. J Ocul Pharmacol Ther 2011;31(2):100-105
11 Park HY,Kim SJ,Lee HB,et al. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea 2008;27(10):1151-1155
12 Bakri SJ,Snyder MR,Reid JM,et al. Pharmacokinetics of intravitreal bevacizumab(Avastin). Ophthalmology 2007;114(5):855-859
13 Chiang CC,Chen WL,Lin JM,et al. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 2008;146(5):688-691
14 Pérez-Rico C,Benítez-Herreros J,Castro-Rebollo M,et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 2010;29(8):849-852
15 Li X,Xu G,Wang Y,et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study. Ophthalmology 2014; 121(9):1740-1747
16 Qu J,Cheng Y,Li X,et al. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy:Subgroup Analysis of the Aurora Study. Retina 2016;36(5):926-937
2 Hosny MH,Zayed MA,Shalaby AM,et al. Effect of intracameral bevacizumab injection on corneal endothelial cells:an in vivo evaluation. J Ocul Pharmacol Ther 2009;25(6):513-517
3 Li H,Lei N,Zhang M,et al. Pharmacokinetics of a long-lasting anti-VEGF fusion protein in rabbit. Exp Eye Res 2012;97(1):154-159
4 Cui J,Sun D,Lu H,et al. Comparison of effectiveness and safety between conbercept and ranibizumab for treatment of neovascular age-related macular degeneration. A retrospective case-controlled non-inferiority multiple center study. Eye(Lond) 2018;32(2):391-399
5 Xu Y,Rong A,Xu W,et al. Comparison of 12-month therapeutic effect of conbercept and ranibizumab for diabetic macular edema:a real-life clinical practice study. BMC Ophthalmol 2017;17(1):158
6 Qiao G,Dong WJ,Dai Y,et al. Diabetic macular edema in proliferative stage treated with anti-vascular endothelial growth factor agent and triamcinolone acetonide by laser-based strategies. Int J Ophthalmol 2017;10(7):1113-1119
7詹磊,熊思盈,甘孟欣,等.玻璃体切割联合白内障手术对DR患者角膜内皮细胞的影响.国际眼科杂志 2017; 17(8):1529-1531
8 Han KY,Chang JH,Lee H,et al. Proangiogenic Interactions of Vascular Endothelial MMP14 With VEGF Receptor 1 in VEGFA-Mediated Corneal Angiogenesis. Invest Ophthalmol Vis Sci 2016;57(7):3313-3322
9 Zhang X,Di G,Dong M,et al. Epithelium-derived miR-204 inhibits corneal neovascularization. Exp Eye Res 2018;167:122-127
10 Ari S,Nergiz Y,Aksit I,et al. Evaluation of intracameral injection of ranibizumab and bevacizumab on the corneal endothelium by scanning electron microscopy. J Ocul Pharmacol Ther 2011;31(2):100-105
11 Park HY,Kim SJ,Lee HB,et al. Effect of intracameral bevacizumab injection on corneal endothelium in rabbits. Cornea 2008;27(10):1151-1155
12 Bakri SJ,Snyder MR,Reid JM,et al. Pharmacokinetics of intravitreal bevacizumab(Avastin). Ophthalmology 2007;114(5):855-859
13 Chiang CC,Chen WL,Lin JM,et al. Effect of bevacizumab on human corneal endothelial cells: a six-month follow-up study. Am J Ophthalmol 2008;146(5):688-691
14 Pérez-Rico C,Benítez-Herreros J,Castro-Rebollo M,et al. Effect of intravitreal ranibizumab on corneal endothelium in age-related macular degeneration. Cornea 2010;29(8):849-852
15 Li X,Xu G,Wang Y,et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration:results from a 12-month randomized phase 2 study:AURORA study. Ophthalmology 2014; 121(9):1740-1747
16 Qu J,Cheng Y,Li X,et al. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy:Subgroup Analysis of the Aurora Study. Retina 2016;36(5):926-937